AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Jul 12, 2023
32254_dirs_2023-07-12_97e012df-63d5-453e-98d9-39f29ea96dfb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-07-11
Reporting Person: Zaderej Karen L. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-07-11 | Common Stock | M | 2000.00 | $0.00 | Acquired | 2000.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-07-11 | Restricted Stock Units | $0.00 | M | 2000.00 | Disposed | Common Stock (2000.00) | Direct |
Footnotes
F1: The restricted stock units vest in three equal annual installments beginning July 11, 2023.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7